Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
PaperCitations, authors & open-access status
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 354 citations, 2022 year and hybrid oa status.
354
Citations
2022
Year
hybrid
OA Status